Search Results 91-100 of 17393 for hba1c

1. A Study To Evaluate Atumelnant In Adults With Congenital Adrenal Hyperplasia - Mayo Clinic

   Poorly controlled diabetes mellitus defined as having an HbA1c ≥8.5% (≥69 mmol/mL) or estimated HbA1c based on fructosamine if HbA1c is not evaluable (eg, due ...

2. rs7903146 genotype on islet GLP-1 production in humans - Mayo Clinic

   HbA1c ³ 6.5%; Use of any glucose-lowering agents including metformin or sulfonylureas. For female subjects: positive pregnancy test at the time of enrollment ...

3. Diabetes care: 10 ways to avoid complications - Mayo Clinic

   Reduced blood flow in the legs and feet, which can lead to infections, nonhealing ulcers and possible amputation; Worse blood sugar control; Heart disease ...

4. Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants - Mayo Clinic

   Have glycosylated hemoglobin (HbA1c) greater than (>) 12 percent (%). Have other structural diseases/conditions that affect the gastrointestinal (GI) system ...

5. A Study To Evaluate The Safety, Tolerability, And Effects On Blood And Urine Markers Of Single Ascending Dose Of GSK4771261 In Healthy Participants And Participants With Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

   HbA1c >=48 millimoles per mole (mmol/mol) (>=6.5%) at screening. Bone fracture within 6 months prior to screening, or presence of a known unresolved or ...

6. A Study to Establish a Biobank of Blood Samples to Study the Relationship Between Diabetes Mellitus and Other Pancreatic Conditions - Mayo Clinic

   Hemoglobin A1c (HbA1c) ≥ 6.5%; Random Blood Glucose (RBG) ≥200 mg/dl; 2h Post Glucose (PG) ≥200mg (11.1 mmol/L) during OGTT (oral glucose tolerance test).

7. Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes - Mayo Clinic

   HbA1c ≥ 6.5%; Use of glucose-lowering agents. For female subjects: positive pregnancy test at the time of enrollment or study; History of prior upper ...

8. A Study of the Effect of Colesevelam on Glucose Metabolism in Patients with Type 2 Diabetes - Mayo Clinic

   HbA1c greater than 9.0%; Have not been stable on all medications for a period exceeding 3 months; Use of drugs or agents within the past 2 weeks or planned ...

9. SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome - Mayo Clinic

   Insulin-resistance may also be defined by abnormal HOMA-IR > 2.5 or by CGM data (e.g., mean glucose, glycemic variability, time in range, estimated HbA1c).

10. A Study to Evaluate the Impact on NASH with Fibrosis of Obeticholic Acid Treatment - Mayo Clinic

    HbA1c > 9.5% within 60 days before Day 1. Evidence of other forms of known chronic liver disease including: Positive test result at Screening for hepatitis ...